{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-023937","form_type":"8-K","ticker":"NTRB","cik":"0001676047","company_name":"NutriBand Inc.","filed_at":"2023-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.101728+00:00","generated_at":"2026-06-17T10:38:38.382302+00:00","sec_items":["7.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Nutriband secures $2M credit line for AVERSA Fentanyl commercialization","bullets":["Three-year $2,000,000 credit line at 7% interest, non-convertible to common stock.","Proceeds to fund FDA approval process and commercial manufacturing of AVERSA Fentanyl.","AVERSA Fentanyl is an abuse-deterrent fentanyl transdermal system using proprietary technology.","Potential peak annual US sales estimated at $80M-$200M per 2022 market analysis.","Financing is non-dilutive, supporting growth strategy without equity dilution."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-023937","json":"https://secwatch.observer/filing/0001213900-23-023937.json","markdown":"https://secwatch.observer/filing/0001213900-23-023937.md","text":"https://secwatch.observer/filing/0001213900-23-023937.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1676047/000121390023023937/0001213900-23-023937-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1676047/000121390023023937/ea175942-8k_nutriband.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T10:38:38.382302+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}